清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

埃罗替尼 医学 长春瑞滨 内科学 肿瘤科 肺癌 表皮生长因子受体 盐酸厄洛替尼 临床终点 危险系数 临床研究阶段 化疗 癌症 临床试验 顺铂 置信区间
作者
Dongsheng Yue,Shidong Xu,Qun Wang,Xiaofei Li,Yi Shen,Heng Zhao,Chun Chen,Weimin Mao,Wei Yong Liu,Junfeng Liu,Lanjun Zhang,Haitao Ma,Qiang Li,Yue Yang,Yongyu Liu,Haiquan Chen,Zhenfa Zhang,Bin Zhang,Changli Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (34): 3912-3917 被引量:73
标识
DOI:10.1200/jco.22.00428
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The randomized, open-label, phase II EVAN study investigated the efficacy (disease-free survival [DFS] and 5-year overall survival [OS]) and safety of erlotinib versus vinorelbine/cisplatin as adjuvant chemotherapy after complete resection (R0) for stage III epidermal growth factor receptor ( EGFR) mutation+ non–small-cell lung cancer. We describe the updated results at the 43-month follow-up. In EVAN, patients were randomly assigned (1:1) to erlotinib (n = 51) or vinorelbine/cisplatin (n = 51). The median follow-up was 54.8 and 63.9 months in the erlotinib and chemotherapy arms, respectively. With erlotinib, the respective 5-year DFS by Kaplan-Meier analysis was 48.2% (95% CI, 29.4 to 64.7) and 46.2% (95% CI, 27.6 to 62.9) in the intention-to-treat and per-protocol populations. The median OS was 84.2 months with erlotinib versus 61.1 months with chemotherapy (hazard ratio, 0.318; 95% CI, 0.151 to 0.670). The 5-year survival rates were 84.8% and 51.1% with erlotinib and chemotherapy, respectively. In whole-exome sequencing analysis, frequent genes with variants co-occurring at baseline were TP53, MUC16, FAM104B, KMT5A, and DNAH9. With erlotinib, a single-nucleotide polymorphism mutation in UBXN11 was associated with significantly worse DFS ( P = .01). To our knowledge, this study is the first to demonstrate clinically meaningful OS improvement with adjuvant erlotinib compared with chemotherapy in R0 stage III EGFR+ non–small-cell lung cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉乐曲完成签到,获得积分10
6秒前
9秒前
美好的飞兰完成签到,获得积分10
17秒前
爆米花的应助被369ninja采纳,获得10
18秒前
32秒前
JUN完成签到,获得积分10
39秒前
瞿人雄完成签到,获得积分10
44秒前
没心没肺完成签到,获得积分10
48秒前
Jasper的应助被科研通管家采纳,获得10
50秒前
50秒前
丘比特的应助被科研通管家采纳,获得10
50秒前
上官若男的应助被科研通管家采纳,获得10
50秒前
Ava的应助被科研通管家采纳,获得10
50秒前
大意的之柔完成签到,获得积分10
53秒前
55秒前
58秒前
369ninja发布了新的文献求助10
1分钟前
可靠往事完成签到,获得积分10
1分钟前
自由的梦山完成签到,获得积分10
1分钟前
喜悦如萱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
学霸业的应助被369ninja采纳,获得10
2分钟前
369ninja发布了新的文献求助10
2分钟前
2分钟前
43tg完成签到,获得积分10
2分钟前
qfhbg完成签到,获得积分10
2分钟前
落后哈密瓜完成签到,获得积分10
2分钟前
wetg完成签到,获得积分10
2分钟前
学霸业的应助被369ninja采纳,获得10
2分钟前
portik完成签到,获得积分10
2分钟前
要减肥的菀完成签到,获得积分10
2分钟前
hgjk完成签到,获得积分10
2分钟前
2分钟前
sdf完成签到,获得积分10
2分钟前
VDC的应助被369ninja采纳,获得30
2分钟前
amz完成签到,获得积分10
2分钟前
adefgv完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179961
求助须知:如何正确求助?哪些是违规求助? 9570183
关于积分的说明 21808480
捐赠科研通 7775832
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557373
邀请新用户注册赠送积分活动 2478958